Literature DB >> 30998507

Prohibitin promotes de-differentiation and is a potential therapeutic target in neuroblastoma.

Ian C MacArthur1,2, Yi Bei1, Heathcliff Dorado Garcia1, Michael V Ortiz3, Joern Toedling1, Filippos Klironomos1, Jana Rolff4, Angelika Eggert1,5,6, Johannes H Schulte1,5,6, Alex Kentsis3,7, Anton G Henssen1,5,6,8.   

Abstract

Gain of the long arm of chromosome 17 (17q) is a cytogenetic hallmark of high-risk neuroblastoma, yet its contribution to neuroblastoma pathogenesis remains incompletely understood. Combining whole-genome and RNA sequencing of neuroblastomas, we identified the prohibitin (PHB) gene as highly expressed in tumors with 17q gain. High PHB expression correlated with poor prognosis and was associated with loss of gene expression programs promoting neuronal development and differentiation. PHB depletion induced differentiation and apoptosis and slowed cell cycle progression of neuroblastoma cells, at least in part through impaired ERK1/2 activation. Conversely, ectopic expression of PHB was sufficient to increase proliferation of neuroblastoma cells and was associated with suppression of markers associated with neuronal differentiation and favorable neuroblastoma outcome. Thus, PHB is a 17q oncogene in neuroblastoma that promotes tumor cell proliferation, and de-differentiation.

Entities:  

Keywords:  Cancer; Genetics; Oncogenes; Oncology

Mesh:

Substances:

Year:  2019        PMID: 30998507      PMCID: PMC6542629          DOI: 10.1172/jci.insight.127130

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  64 in total

Review 1.  Targeting of proteins to mitochondria.

Authors:  T Lithgow
Journal:  FEBS Lett       Date:  2000-06-30       Impact factor: 4.124

2.  Prohibitin co-localizes with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repression.

Authors:  Sheng Wang; Gina Fusaro; Jaya Padmanabhan; Srikumar P Chellappan
Journal:  Oncogene       Date:  2002-12-05       Impact factor: 9.867

3.  Genomic and expression profiling of chromosome 17 in breast cancer reveals complex patterns of alterations and novel candidate genes.

Authors:  Béatrice Orsetti; Mélanie Nugoli; Nathalie Cervera; Laurence Lasorsa; Paul Chuchana; Lisa Ursule; Catherine Nguyen; Richard Redon; Stanislas du Manoir; Carmen Rodriguez; Charles Theillet
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

4.  Positive and negative regulation of Raf kinase activity and function by phosphorylation.

Authors:  H Chong; J Lee; K L Guan
Journal:  EMBO J       Date:  2001-07-16       Impact factor: 11.598

5.  17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group.

Authors:  N Bown; M Lastowska; S Cotterill; S O'Neill; C Ellershaw; P Roberts; I Lewis; A D Pearson
Journal:  Med Pediatr Oncol       Date:  2001-01

6.  Induced neuroblastoma cell differentiation, associated with transient HES-1 activity and reduced HASH-1 expression, is inhibited by Notch1.

Authors:  A Grynfeld; S Påhlman; H Axelson
Journal:  Int J Cancer       Date:  2000-11-01       Impact factor: 7.396

7.  Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.

Authors:  N Bown; S Cotterill; M Lastowska; S O'Neill; A D Pearson; D Plantaz; M Meddeb; G Danglot; C Brinkschmidt; H Christiansen; G Laureys; F Speleman; J Nicholson; A Bernheim; D R Betts; J Vandesompele; N Van Roy
Journal:  N Engl J Med       Date:  1999-06-24       Impact factor: 91.245

8.  Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

Authors:  K K Matthay; J G Villablanca; R C Seeger; D O Stram; R E Harris; N K Ramsay; P Swift; H Shimada; C T Black; G M Brodeur; R B Gerbing; C P Reynolds
Journal:  N Engl J Med       Date:  1999-10-14       Impact factor: 91.245

9.  The human prohibitin gene located on chromosome 17q21 is mutated in sporadic breast cancer.

Authors:  T Sato; H Saito; J Swensen; A Olifant; C Wood; D Danner; T Sakamoto; K Takita; F Kasumi; Y Miki
Journal:  Cancer Res       Date:  1992-03-15       Impact factor: 12.701

Review 10.  Retinoid therapy of high-risk neuroblastoma.

Authors:  C Patrick Reynolds; Katherine K Matthay; Judith G Villablanca; Barry J Maurer
Journal:  Cancer Lett       Date:  2003-07-18       Impact factor: 8.679

View more
  6 in total

1.  LncRNA RUS shapes the gene expression program towards neurogenesis.

Authors:  Marius F Schneider; Veronika Müller; Stephan A Müller; Stefan F Lichtenthaler; Peter B Becker; Johanna C Scheuermann
Journal:  Life Sci Alliance       Date:  2022-06-10

2.  Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor.

Authors:  Michael V Ortiz; Saima Ahmed; Melissa Burns; Anton G Henssen; Travis J Hollmann; Ian MacArthur; Shehana Gunasekera; Lyvia Gaewsky; Gary Bradwin; Jeremy Ryan; Anthony Letai; Ying He; Arlene Naranjo; Yueh-Yun Chi; Michael LaQuaglia; Todd Heaton; Paolo Cifani; Jeffrey S Dome; Samantha Gadd; Elizabeth Perlman; Elizabeth Mullen; Hanno Steen; Alex Kentsis
Journal:  JCI Insight       Date:  2019-08-08

Review 3.  Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs.

Authors:  Roberto Ciaccio; Piergiuseppe De Rosa; Sara Aloisi; Marta Viggiano; Leonardo Cimadom; Suleman Khan Zadran; Giovanni Perini; Giorgio Milazzo
Journal:  Int J Mol Sci       Date:  2021-11-28       Impact factor: 5.923

Review 4.  Prohibitins: A Key Link between Mitochondria and Nervous System Diseases.

Authors:  Tianlin Jiang; Jiahua Wang; Chao Li; Guiyun Cao; Xiaohong Wang
Journal:  Oxid Med Cell Longev       Date:  2022-07-08       Impact factor: 7.310

5.  Therapeutic targeting of ATR in alveolar rhabdomyosarcoma.

Authors:  Heathcliff Dorado García; Fabian Pusch; Yi Bei; Jennifer von Stebut; Glorymar Ibáñez; Kristina Guillan; Koshi Imami; Dennis Gürgen; Jana Rolff; Konstantin Helmsauer; Stephanie Meyer-Liesener; Natalie Timme; Victor Bardinet; Rocío Chamorro González; Ian C MacArthur; Celine Y Chen; Joachim Schulz; Antje M Wengner; Christian Furth; Birgit Lala; Angelika Eggert; Georg Seifert; Patrick Hundsoerfer; Marieluise Kirchner; Philipp Mertins; Matthias Selbach; Andrej Lissat; Frank Dubois; David Horst; Johannes H Schulte; Simone Spuler; Daoqi You; Filemon Dela Cruz; Andrew L Kung; Kerstin Haase; Michela DiVirgilio; Monika Scheer; Michael V Ortiz; Anton G Henssen
Journal:  Nat Commun       Date:  2022-07-25       Impact factor: 17.694

6.  Prohibitin participates in the HIRA complex to promote cell metastasis in breast cancer cell lines.

Authors:  Xiaoqing Huang; Jinji Liu; Qinghui Ma
Journal:  FEBS Open Bio       Date:  2020-09-21       Impact factor: 2.792

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.